LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RNXT
RenovoRx, Inc.
There isn't enough reported data to score RNXT yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RNXT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
RNXT's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RNXT PE Valuation
RNXT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RNXT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RNXT's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RNXT on earnings quality, reporting a profit while its opponent remains loss making.
RNXT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.06 |
| Q2 2026 | -$0.31 | +$0.08 |
| Q1 2026 | -$0.33 | +$0.08 |
| Q4 2025 | -$0.32 | +$0.08 |
| Q3 2025 | -$0.37 | +$0.18 |
| Q2 2025 | -$0.39 | +$0.19 |
| Q1 2025 | -$0.41 | +$0.29 |
| Q4 2024 | -$0.40 | +$0.59 |
RNXT is still losing money, but far less than before: $0.31 per share over the past year, against $1.13 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RNXT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RNXT on profitability, with a higher operating margin.
RNXT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | +301% |
| Q2 2026 | $909K | +115% |
| Q1 2026 | $563K | +186% |
RNXT's revenue has grown year over year for seven quarters in a row: $1M last quarter, up 301% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -304% | +900 points |
| Q2 2026 | -368% | +266 points |
| Q1 2026 | -616% | +963 points |
| Q4 2025 | -1480% | N/A |
| Q3 2025 | -1203% | N/A |
| Q2 2025 | -635% | N/A |
| Q1 2025 | -1579% | N/A |
RNXT's operating margin was −304% last quarter, up 899 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RNXT on cash generation, producing positive trailing cash flow while its opponent burns cash.
RNXT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.6M | -$288K |
| Q2 2026 | -$2.9M | -$636K |
| Q1 2026 | -$3.7M | -$326K |
| Q3 2025 | -$2.3M | -$76K |
| Q2 2025 | -$2.3M | -$5K |
| Q1 2025 | -$3.4M | -$1.2M |
| Q3 2024 | -$2.2M | +$534K |
| Q2 2024 | -$2.3M | +$474K |
RNXT has burned cash in almost every quarter: −$12M over the past year, against −$10M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RNXT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RNXT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +896K shares |
| 1 year | +32% | +11.6M shares |
| 3 years | +432% | +39.1M shares |
| 5 years | +187% | +31.4M shares |
RNXT has 48M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RNXT Net Leverage
RNXT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RNXT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.5 | Neutral |
| Stochastic | 19.2 | Oversold |
RNXT's weekly RSI is 48 (neutral) and its Stochastic is 19 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RNXT PE vs Healthcare Sector
RNXT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RNXT on trend strength, trading above more of its moving averages.
RNXT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 12% below |
| 20 week MA | $1.32 | 12% below |
| 50 week MA | $1.09 | 6.4% above |
| 100 week MA | $1.12 | 3.6% above |
| 200 week MA | $1.40 | 17% below |
RNXT's trend is mixed: it's above two of its five weekly moving averages, and 17% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
RNXT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $7.71 | $5.09 | -34% |
| 2022 | $5.09 | $1.97 | -61% |
| 2023 | $1.97 | $2.29 | +16% |
| 2024 | $2.29 | $1.30 | -43% |
| 2025 | $1.30 | $0.85 | -35% |
| 2026 YTD | $0.85 | $1.16 | +36% |
RNXT has the edge over LLY on returns for 2026, with the stronger performance.